Want to see OTLK full AI Analyst Report?
Outlook Therapeutics (OTLK) Income Statement
Outlook Therapeutics Income Statement
Last quarter (Q3 2026), Outlook Therapeutics's total revenue was $9.00K, a decrease of 99.40% from the same quarter last year. In Q3, Outlook Therapeutics's net income was $-20.32M. See Outlook Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Sep 25 | Sep 24 | Sep 23 | Sep 22 | Sep 21 |
|---|---|---|---|---|---|
| $ 1.41M | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ 657.21K | $ 0.00 | $ 0.00 | $ -204.69K | $ 0.00 | |
| $ 67.72M | $ 71.70M | $ 53.13M | $ 62.87M | $ 51.73M | |
| Depreciation and Amortization | $ 117.05K | $ 113.86K | $ 44.19K | $ 204.69K | $ 262.14K |
| $ -63.58M | $ -72.09M | $ -56.40M | $ -64.36M | $ -51.96M | |
| $ -67.06M | $ -71.70M | $ -53.13M | $ -63.07M | $ -51.73M | |
| $ 3.08M | $ -3.66M | $ -5.85M | $ -2.98M | $ -1.43M | |
| $ -63.98M | $ -75.36M | $ -58.98M | $ -66.05M | $ -53.16M | |
| $ -62.42M | $ -75.37M | $ -58.98M | $ -66.05M | $ -53.16M | |
| Per Share Metrics | |||||
| Basic EPS | $ -1.79 | $ -4.06 | $ -4.80 | $ -6.23 | $ -7.00 |
| Diluted EPS | $ -1.79 | $ -4.06 | $ -4.80 | $ -6.23 | $ -7.00 |
| Weighted Average Shares Outstanding | 25.48M | 18.55M | 12.51M | 10.60M | 7.63M |
| Weighted Average Shares Outstanding (Diluted) | 25.48M | 18.55M | 12.51M | 10.60M | 7.63M |
Currency in USD